Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Tianjin Tiancheng Pharma. Co., Ltd.","sponsor":"Grifols International","pharmaFlowCategory":"D","amount":"$1,281.5 million","upfrontCash":"Undisclosed","newsHeadline":"Grifols Acquires Tiancheng Pharmaceutical Holdings, the Largest Shareholder of Biotest, to Increase Patients\u2019 Access to Plasma Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Tianjin Tiancheng Pharma. Co., Ltd.

    Menu

    Tianjin Tiancheng Pharma. Co., Ltd.

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Tianjin Tiancheng Pharma. Co., Ltd.

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Grifols Acquires Tiancheng Pharmaceutical Holdings, the Largest Shareholder of Biotest, to Increase Patients’ Access to Plasma Therapies

              Details:

              This acquisition will significantly reinforce Grifols’ industry capabilities by enhancing its plasmaderived medicines access, pipeline Biotest is leading clinical trials on plasma-derived fibrinogen (BT524) to treat congenital and acquired disorders.

              Lead Product(s): BT524

              Therapeutic Area: Genetic Disease Product Name: BT524

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Grifols International

              Deal Size: $1,281.5 million Upfront Cash: Undisclosed

              Deal Type: Acquisition September 17, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY